Release date: 3/15/22
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting viral illness termed COVID-19 first appeared in late 2019 and rapidly became a pandemic. As of 1/6/2022, at least 295,218,167 people worldwide have been infected with the virus, including 57,745,899 in the United States, which has led to 5,457,474 deaths worldwide and 830,549 in the United States. The rapid development and deployment of vaccinations have helped to minimize viral transmission and reduced the morbidity and mortality of infections among those who do contract the virus. However, as of December 15, 2021, only 72.1% of the total US population had received at least one dose of an approved COVID-19 vaccine, and approximately 62% had received both doses of the 2-dose options, leaving at least one in 4 eligible adult Americans unvaccinated.1 It is difficult to track the number of people who have received the third or booster doses; at least 100 million Americans had received it by January 2022.2 Despite vaccinations (with or without boosters), there continue to be breakthrough infections, particularly as new variants emerge that appear refractory to current vaccinations.
This educational initiative is directed toward All healthcare providers including physicians, nurses, PAs, social workers, NPs, etc.
Upon completion of the educational activity, participants should be able to:
• Identify the current VOI and VOC in the US.
• Explain the effects of the current VOCs with regard to susceptibility to available treatments.
• Specify the efficacy and clinical trial data for the use of monoclonal antibodies for treatment of mild-to-moderate COVID-19 and post-exposure prophylaxis.
• Develop strategies that enable appropriate patients to receive monoclonal antibody treatments.
• Discuss the efficacy and clinical trial data for the use of new oral antiviral treatments for mild-to-moderate COVID-19.
• Develop strategies that enable patients to receive oral treatments to manage mild-to-moderate COVID-19.
• Specify patient criteria for receipt of pre-exposure prophylaxis.
• List common sources of disparities regarding the prevention and management of COVID-19.
• Develop strategies to address healthcare disparities influencing prevention and treatment of COVID-19.
Criteria for Success
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at [email protected]
CE Credit jointly provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Credit being awarded: 1.0 ANCC contact hours
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.0 contact hours.
As a Jointly Accredited Organization, AKH Inc., Advancing Knowledge in Healthcare is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. AKH Inc. Advancing Knowledge in Healthcare maintains responsibility for this course. Social workers completing this course receive 1.0 continuing education credits.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity.
Joseph DeRose, DO (author)
Lynne Kolton Schneider, PhD (author)
Jennifer Pollard Ruiz, MD MPH (author)
Dorothy Duffy, BS Pharmacy (reviewer)
Broc Pollinger MSW, LSW, OSW-C (reviewer)
Deborah C. Clark, PhD Senior Director of Professional Development
Dorothy Caputo, MA, BSN, RN Senior Director of Continuing Education & Compliance
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated.
This educational activity is supported by an educational grant from GlaxoSmithKline.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.